Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial

The Lancet Oncology

Volumn 17, Issue 5, 2016, Pages 651-662

  Nywening, Timothy M ^a,c   Wang Gillam, Andrea ^a,c   Sanford, Dominic E ^a   Belt, Brian A ^d   Panni, Roheena Z ^a   Cusworth, Brian M ^a,c   Toriola, Adetunji T ^a,c   Nieman, Rebecca K ^a,c   Worley, Lori A ^a,c   Yano, Motoyo ^b,c   Fowler, Kathryn J ^b,c   Lockhart, A Craig ^a,c   Suresh, Rama ^a,c   Tan, Benjamin R ^a,c   Lim, Kian Huat ^a,c   Fields, Ryan C ^a,c   Strasberg, Steven M ^a,c   Hawkins, William G ^a,c   DeNardo, David G ^a,c   Goedegebuure, S Peter ^a,c   Linehan, David C ^d   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Washington University in St Louis School of Medicine   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LIVER ENZYME; OXALIPLATIN; PF 04136309; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CCR2 PROTEIN, HUMAN; PF-04136309; PLATINUM COMPLEX; PYRROLIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; ALOPECIA; ANEMIA; ARTICLE; BOLUS INJECTION; CANCER CONTROL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOKALEMIA; IMAGING SYSTEM; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; SIDE EFFECT; TARGET CELL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UNITED STATES; VOMITING; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; MACROPHAGE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PROGNOSIS; PYRROLIDINES; RECEPTORS, CCR2;

EID: 84962367349     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00078-4     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M Pancreatic cancer. Lancet 2011, 378:607-620.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691-1703.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
5. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007, 67:9518-9527.
6. Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013, 73:1128-1141.
7. Sanford DE, Belt BA, Panni RZ, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 2013, 19:3404-3415.
8. Shi C, Pamer EG Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011, 11:762-774.
9. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
10. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
11. Zhao L, Lim SY, Gordon-Weeks AN, et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology 2013, 57:829-839.
12. Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol 2015, 22:295-301.
13. Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013, 18:543-548.
14. Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013, 108:236-241.
15. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012, 12:199.
16. Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012, 13:497-501.
17. Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from alliance trial A021101. Proc Am Soc Clin Oncol 2015, 33(suppl):4008. (abstr).
18. Qian BZ, Pollard JW Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
19. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
20. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010, 184:3106-3116.
21. Bronte V, Zanovello P Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005, 5:641-654.
22. Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 2015, 16:949-956.
23. Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 2015, 373:428-437.
24. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
25. Pienta KJ, Machiels JP, Schrijvers D, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 2013, 31:760-768.
26. Fetterly GJ, Aras U, Meholick PD, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol 2013, 53:1020-1027.
27. Bonapace L, Coissieux MM, Wyckoff J, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 2014, 515:130-133.
28. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73.
29. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011, 1:54-67.
30. Nakasone ES, Askautrud HA, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.